SCHEMBL24316293

SCHEMBL24316293

COc1ccccc1OC1CN(C2CCCC(OC(C)C)C2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
PDE9A O76083 2/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A3 Q01959 2/20 0.36
PDE4B Q07343 1/20 0.35
PDE4A P27815 1/20 0.35
GLRA3 O75311 1/20 0.35
GLRB P48167 1/20 0.35
TACR1 P25103 1/20 0.35
CHRM4 P08173 2/20 0.35
CHRM5 P08912 2/20 0.35
HRH1 P35367 2/20 0.35
SIGMAR1 Q99720 2/20 0.35
CHRM2 P08172 1/20 0.35
ADRA2A P08913 1/20 0.35
CHRM1 P11229 1/20 0.35
DRD2 P14416 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
CHRM3 P20309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26619745 0.87 ALDH1A1 (0.45) ALDH1A1PDE9ASLC6A2SLC6A3PDE4B
SCHEMBL24317560 0.87 HSD11B1 (0.38) SLC6A2SLC6A3HRH1CHRM1SLC6A4
SCHEMBL26632835 0.85 ALDH1A1 (0.43) ALDH1A1SLC6A2SLC6A3PDE4BGLRA3
SCHEMBL27010170 0.85 DRD2 (0.38) PDE9ASLC6A2SLC6A3GLRA3GLRB
SCHEMBL21622139 0.81 ABCB1 (0.49) ALDH1A1PDE9APDE4BGLRA3GLRB
SCHEMBL24316300 0.81 SLC6A2 (0.48) PDE9ASLC6A2SLC6A3SLC6A4OPRM1
SCHEMBL25999839 0.80 ABCB1 (0.51) ALDH1A1PDE4BGLRA3GLRBSIGMAR1
SCHEMBL24317563 0.79 HRH3 (0.45) PDE9ASLC6A2SLC6A3HRH1SIGMAR1
SCHEMBL27010177 0.78 PDE4B (0.36) PDE9APDE4BPDE4AGLRA3GLRB
SCHEMBL27010152 0.77 DPP4 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
US-9585884-B2 Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC. (US) 2017-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 ALDH1A1 2267/4885PDE9A 3476/4885SLC6A2 2569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.